EOFlow Officially Launche...
▶ iOS version of the world’s first app for controlling wearable insulin pump ▶ Improved ease of use by replacing a portable controller with a smartphone app EOFlow Co., Ltd. (KOSDAQ: 294090) (EOFlow or the Company), a provider of wearable drug delivery solutions, today announces that it offic...
May.17.2022
EOFlow Announces Record R...
▶ Highest-ever quarterly revenue! Strong revenue growth from European sales; Menarini will progressively launch the product in Europe from 2Q22 onwards! ▶ EOFlow expects significant growth in revenue in 2022 from market launches in Europe, Indonesia, and the Middle East EOFlow Co., Ltd. (KOSDAQ: 29...
May.16.2022
EOFlow Has its First Clin...
▶ A 4-Week, Two-Center, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of EOPatch in Well-Controlled Type 1 Diabetes Mellitus ▶ 4-week treatment with EOPatch was safe and led to clinically meaningful improvement in glycemic control compared to those with MDI or conventional insulin...
Apr.11.2022
EOFlow to Supply KRW48.8b...
▶ A Major Export Deal for EOFlow’s Innovative Insulin Pump EOPatch EOFlow Co. Ltd. (KOSDAQ: 294090) (EOFlow or the Company), a provider of wearable drug delivery solutions, has announced on March 31 that it has signed a contract with GulfDrug LLC (Gulf Drug) of the United Arab Emirates (UAE) ...
Apr.04.2022
EOFlow Announces Board Me...
▶ Mr. Luis Malave will put more focus on the US market as EOFlow’s US president ▶ EOFlow will appoint Mr. CJ Kim as a new board member Mar. 10, 2022 - EOFlow Co., Ltd. (KOSDAQ: 294090) (EOFlow or the Company), wearable healthcare company, announced on March 8th that the Company’s b...
Mar.10.2022
EOFlow Holds a Clinical R...
▶ “EOPatch X” is a two-part wearable artificial pancreas (AP) solution that automatically adjusts basal insulin delivery based on the user’s glucose level ▶ EOFlow shows commitment to support for successful completion of clinical trial EOFlow Co., Ltd. (KOSDAQ: 294090) (EOFlow or ...
Mar.07.2022
[Edaily news] Analysis on...
EOFlow's founding CEO Jesse Kim's interview articles were published at edaily on March 4th. Mr. Kim explained fully from company history to the long-term plan. For the full 3 articles, please see the link below (in Korean only): 1. Top-tier global team- MIT graduate founding CEO and ...
Mar.04.2022
[Edaily CEO interview] Re...
EOFlow's founder and CEO Jesse Kim had an interview with edaily on February 16. He announced EOFlow's plan to enter the U.S. market with its current disposable wearable insulin pump 'EOPatch'. The Company will begin its submission process to the Food and Drug Administration (FDA) as...
Feb.18.2022
EOFlow Reports Full Year ...
▶ EOFlow released its consolidated financial statements for the full year of 2021: Revenue of 693 million KRW, Operating loss of 26.9 billion KRW, Net loss of 29.4 billion KRW. ▶ Revenue growth from full launch in Korea (April) and shipment to Europe (September). ▶ Menarini will progressively l...
Feb.15.2022
EOFlow Successfully Raise...
▶113.4 billion Won raised with new common stock offering, followed by a 2:1 stock split ▶Secured long-term growth momentum ▶Aims to focus on global wearable insulin pump market and expand to wearable healthcare market segments EOFlow Co., Ltd. (KOSDAQ: 294090) (EOFlow or the Company), a wearable he...
Feb.08.2022
